mTOR kinase is a therapeutic target for respiratory syncytial virus and coronaviruses

Hoang Dinh Huynh, Ruth Levitz, Rong Huang, Jeffrey S. Kahn

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Therapeutic interventions targeting viral infections remain a significant challenge for both the medical and scientific communities. While specific antiviral agents have shown success as therapeutics, viral resistance inevitably develops, making many of these approaches ineffective. This inescapable obstacle warrants alternative approaches, such as the targeting of host cellular factors. Respiratory syncytial virus (RSV), the major respiratory pathogen of infants and children worldwide, causes respiratory tract infection ranging from mild upper respiratory tract symptoms to severe life-threatening lower respiratory tract disease. Despite the fact that the molecular biology of the virus, which was originally discovered in 1956, is well described, there is no vaccine or effective antiviral treatment against RSV infection. Here, we demonstrate that targeting host factors, specifically, mTOR signaling, reduces RSV protein production and generation of infectious progeny virus. Further, we show that this approach can be generalizable as inhibition of mTOR kinases reduces coronavirus gene expression, mRNA transcription and protein production. Overall, defining virus replication-dependent host functions may be an effective means to combat viral infections, particularly in the absence of antiviral drugs.

Original languageEnglish (US)
Article number24442
JournalScientific reports
Issue number1
StatePublished - Dec 2021

ASJC Scopus subject areas

  • General


Dive into the research topics of 'mTOR kinase is a therapeutic target for respiratory syncytial virus and coronaviruses'. Together they form a unique fingerprint.

Cite this